Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (29979)	1/8/2000 11:26:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Oral Targretin was approved as a second line treatment because CTCL is typically initially treated with a topical or non-systemic agent. In general, most of these patients eventually fail to adequately control their disease and move onto an additional treatment. It seemed that oral Targretin had a clear lead among the second line, systemic treatments which include chemotherapeutic agents which have much harsher side effects. Other agents such as interferon also had major side effects and many patients wanted to stay away from such treatments for as long as possible. What I found most interesting was the fact that even though the patient moved to oral Targretin after being treated with topical Targretin, she still responded, and did so quite satisfactorily. Of course, as you know, LGND has submitted an NDA for topical Targretin, and it too has been granted priority review, so we should have an answer on that one in less than 5 months. The topical approaches are less likely to have side effects, but they do seem to produce a response of limited duration. If approved, LGND will have 3 treatment options for CTCL patients. Initially they will be treated with topical Targretin, followed by oral Targretin, followed by intravenous ONTAK. It is likely that such choices will also have applications for plaque psoriasis.